伊潘立酮(Iloperidone) - 药物靶点：5-HT2A receptor x D2 receptor_在研适应症：躁郁症1型，躁狂，精神分裂症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone、4'-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone、Fanaptum

+ [10]

靶点

5-HT2A receptor x D2 receptor

作用方式

拮抗剂

作用机制

5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

其他疾病神经系统疾病

在研适应症

躁郁症1型躁狂精神分裂症

非在研适应症

急性精神分裂症情绪易怒原发性肥大性骨关节病+ [3]

原研机构

Novartis Pharma AG

在研机构

Novartis AG

Vanda Pharmaceuticals, Inc.

Probiomed SA de CV

非在研机构

Novartis Pharmaceuticals Corp.

权益机构

Novartis AG

Vanda Pharmaceuticals, Inc.Aventis SA

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2009-05-06),

精神分裂症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C24H27FN2O4

InChIKeyXMXHEBAFVSFQEX-UHFFFAOYSA-N

CAS号133454-47-4

关联

32

项与伊潘立酮相关的临床试验

NCT07090161

/ Recruiting临床2期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

开始日期2025-09-15

申办/合作机构

Vanda Pharmaceuticals, Inc.

NCT06961968

/ Recruiting临床3期

A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

开始日期2025-05-14

申办/合作机构

Vanda Pharmaceuticals, Inc.

NCT06494397

/ Completed临床1期

Crossover Bioequivalence Study of 12 mg VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.

开始日期2024-07-11

申办/合作机构

Vanda Pharmaceuticals, Inc.

100 项与伊潘立酮相关的临床结果

登录后查看更多信息

100 项与伊潘立酮相关的转化医学

登录后查看更多信息

100 项与伊潘立酮相关的专利（医药）

登录后查看更多信息

319

项与伊潘立酮相关的文献（医药）

2026-07-01·Clinical Drug Investigation

Milsaperidone: First Approval

Review

作者: Shirley, Matt

Milsaperidone (Bysanti™) is an atypical antipsychotic being developed by Vanda Pharmaceuticals for use in the treatment of schizophrenia, bipolar I disorder, and major depressive disorder. Milsaperidone is an active metabolite of iloperidone (Fanapt^®), an atypical antipsychotic approved in the USA for the treatment of schizophrenia since 2009 and for use in the acute treatment of bipolar I disorder since 2024. With clinical trials demonstrating the pharmacokinetic bioequivalence of milsaperidone and iloperidone, on 20 February 2026, milsaperidone gained approval in the USA for use in the treatment of schizophrenia and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Additionally, milsaperidone is in phase III clinical evaluation for use in the treatment of major depressive disorder. This article summarizes the milestones in the development of milsaperidone leading to this first approval for schizophrenia and bipolar I disorder in adults.

2026-04-01·PHARMACOGENOMICS JOURNAL

A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone

Article

作者: Czeisler, Emily L ; Torres, Rosarelis ; Polymeropoulos, Mihael H ; Birznieks, Gunther ; Polymeropoulos, Christos M ; Xiao, Changfu ; Smieszek, Sandra P ; Bai, Haimeng ; Chadwick, Sean R

Circulating levels of uric acid are influenced by a complex mix of intrinsic and environmental factors, including genetics, diet, and drugs. We analyzed levels of uric acid in a recent phase 3 clinical trial of patients with bipolar mania treated with 24 mg/day of the antipsychotic iloperidone or placebo. Initial results revealed that iloperidone treatment was associated with increases in uric acid from baseline (LS mean change (SE) of 27.2 (-4.93) μmol/L, compared with a change of 0.1 (-4.77) μmol/L for placebo group (LS mean difference (95% CI) = 27.1 (14.94, 39.20), p = <0.0001). Similar results were further observed in a previous phase 3 study of iloperidone treatment of schizophrenia. Pharmacogenetic analysis examining the urate transporter SLC2A9 revealed that iloperidone associated increases were linked to a genetic variant (rs7442295), correlating with both urate levels at baseline and in interaction with iloperidone vs placebo, and a pronounced increase of 35.9 μmol/L (0.67 mg/dL) was seen in iloperidone-treated patients homozygous for the for the rs7442295 (G) allele at the SLC2A9 gene, compared to a decrease of -16.5 (0.31 μmol/L in the corresponding GG placebo group (LS mean difference (95% CI) = 40.79 (14.61, 66.96, p = 0.0024). Further investigation suggested potentially clinically relevant sex differences associated with this variant. Specifically, male GG genotype patients exhibiting more frequent shifts from above the upper limit of normal for iloperidone-treated patients in comparison to female, AG/AA, and placebo groups. Overall, the mechanism of this iloperidone-induced increase in serum urate levels is likely due to decrease in clearance of urate through interaction with the SLC2A9 urate transporter protein. These results may hold clinical significance for patients treated with iloperidone.

2025-11-01·JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

Article

作者: Muto, Chieko ; Kawai, Norisuke ; Fukuhara, Kei ; Tanetsugu, Yusuke ; Wada, Shinsuke

Abstract:

Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ethnic sensitivity assessment. This assessment is recommended by the latest Japanese guideline (issued in December 2023) for Japanese phase 1 studies before participation in multi‐regional clinical trials (MRCTs). To comprehensively understand characteristics and ethnic sensitivity of drugs that seem to have racial/ethnic differences in its disposition and response, we investigated 620 new molecular entities (NMEs) approved by the United States Food and Drug Administration (FDA) between 2008 and 2023. Of those, only 6.5% (40 NMEs) reported racial/ethnic differences in the PK (5.0%), safety (1.6%), and/or efficacy (0.6%) in the FDA drug labeling, with only one NME (0.16%) having a clinically significant PK difference which requires a reduced starting dose in East Asian patients. Additionally, 4.4% of 620 NMEs reported differences in the pharmacogenetics for drug‐metabolizing enzymes. The comprehensive evaluation of characteristics and ethnic sensitivity of 40 NMEs with racial/ethnic differences in the PK, safety, and/or efficacy indicated two key findings. First, participation in MRCTs from various regions as early as possible is much more important than conduct of an additional phase 1 study in a specific region/country. Second, more attention and deeper evaluation of Asian PK would be needed for drugs with low bioavailability in the overall drug development.

116

项与伊潘立酮相关的新闻（医药）

2026-10-17

·摩熵医药

万达生物制药III期临床失败，暂停新药研发！

10月14日，万达生物制药（Vanda Pharmaceuticals）发布公告，旗下新型小分子药物VQW-765用于成人社交焦虑障碍急性发作按需治疗的III期临床研究（3201研究）未达到主要终点，公司决定暂停该项目的进一步研发，待完整数据分析后再作评估。截图来源：万达生物制药企业公告该研究评估了受试者单次口服VQW-765或安慰剂后，在特里尔社会压力测试（TSST）中的焦虑反应。结果显示，在女性意向治疗（ITT）人群中，VQW-765组表现期主观痛苦程度量表（SUDS）均分为65.6，安慰剂组为66.0，差异无统计学意义（p=0.8899），未达到主要终点。关键次要终点同样未达标。在总体男女人群中，VQW-765组SUDS均分为64.7，安慰剂组为63.8，差异无统计学意义（p=0.6605）。尽管疗效终点未达预期，VQW-765在研究中表现出良好的安全性和耐受性，与此前研究结果一致。 VQW-765（曾用名AQW-051）是一种新型小分子α7烟碱型乙酰胆碱受体（α7-nAChR）部分激动剂，最初由诺华研发。来源：摩熵医药全球药物研发数据库（查数据.找摩熵） 2014年12月，万达生物制药与诺华就抗精神病药物Fanapt的许可仲裁达成和解。根据协议，诺华向万达转让Fanapt在美国和加拿大市场的全部权益，并授予万达AQW-051的全球独家许可权，同时对万达进行2500万美元股权投资。此次III期研究失败后，该药后续研发能否继续推进，仍有待公司对完整数据的进一步评估。 END 本文为原创文章，转载请留言获取授权注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。点击阅读原文，申请摩熵医药企业版免费试用！

2026-10-15

·Firstwordpharma

Vanda puts small molecule's social anxiety programme on hold after mid-stage miss

Vanda Pharmaceuticals said Wednesday that its investigational alpha-7 nicotinic acetylcholine receptor partial agonist VQW-765 missed the primary endpoint of a Phase II trial in adults with social anxiety disorder, prompting the company to put a hold on further development in the indication pending analysis of the full dataset."We are disappointed that Study 3201 did not confirm the earlier Phase II findings for VQW-765," said Vanda CEO Mihael H. Polymeropoulos. The previous trial, dubbed Study 2201, top-lined in 2022 showing a trend of improvement in intensity of anxiety with the small-molecule asset.Study 3201 randomised 546 adults aged 18-65 years with social anxiety disorder to receive a single oral dose of VQW-765 or placebo before being challenged with the Trier Social Stress Test (TSST). The primary endpoint was distress among female participants during the TSST performance phase, measured via the 0-100 point Subjective Units of Distress Scale (SUDS), with higher scores indicating greater distress.Results showed a mean SUDS score of 65.6 with VQW-765 compared with placebo's 66.0, translating to a non–significant difference of -0.4 (p=0.8899). Vanda noted a key secondary endpoint — SUDS during the performance phase in the total male and female population — was also missed, at 64.7 versus 63.8 for placebo (difference = 0.9; p=0.6605). Safety-wise, Vanda noted VQW-765 was well tolerated, with its safety profile aligning with prior studies.Novartis out-licensed VQW-765 (formerly AQW051) to Vanda in 2014, as part of a larger settlement agreement between the companies involving the antipsychotic Fanapt (iloperidone).

临床2期临床结果

2026-09-30

·今日头条

FDA今年批了11款CNS新药四分之一名额透露什么信号

截至9月底，FDA CDER今年批准的44款新药里，有11款直接和中枢神经系统挂钩——神经系统罕见病、CNS精准诊断都算在内。四分之一。这个比例搁在五年前，大概率会被当成统计口径出了问题。“CNS无新药”的说法在行业里流传了快二十年，失败率高、安慰剂效应跨不过去、机制说不清楚，大药企一度成批砍掉神经科学管线。所以今年这批名单值得单独拿出来看。经典靶点还在，但打法明显变了 2月获批的Bysanti（milsaperidone）用于精神分裂症和双相I型障碍急性发作。它的身份有点绕：本质上是已上市药物Fanapt（伊潘立酮）的活性代谢物，两者在体内快速互变。 FDA批它靠的是生物等效性数据，不是全新临床试验。与其说是新药，不如说是一次基于代谢物化学特性的生命周期延伸。 7月的Simtriyo（centanafadine）走的是另一条路。它是首个同时抑制去甲肾上腺素、多巴胺和5-羟色胺再摄取的ADHD药物。兴奋剂和单一机制非兴奋剂主导这个领域很多年了，三重再摄取提供的是第三种药理学路径。三期数据里，成人患者用药后ADHD评分改善约10分，安慰剂组约7分，效应量落在0.4上下。大冢制药在新闻稿里把它定位为“first-in-class的NDSRI”。 9月底的Juvmo（tavapadon）则是帕金森病领域一次受体层面的精细化操作。它是首个选择性靶向多巴胺D1/D5受体亚型的部分激动剂，不像传统药物那样笼统刺激多巴胺系统。 TEMPO三期项目里，15mg剂量组26周时将患者日常活动评分改善约10分，安慰剂组反而恶化了。三款药都踩在经典神经递质系统上，做法完全不同：代谢物再开发、三重机制叠加、受体亚型精准靶向。粗放式的“找到新靶点”不够用了，药物设计的颗粒度在变细。 “补回缺失的东西”，机制型药物开始集中落地 8月5日，Takeda的Orzeyful（oveporexton）获批用于1型发作性睡病。这款药的特殊之处在于治疗逻辑换了方向：发作性睡病1型的核心病理是食欲素神经元丢失导致信号不足，oveporexton作为口服食欲素受体2激动剂，直接补充缺失的信号。过去的治疗是用兴奋剂对抗白天嗜睡、用抗抑郁药压制猝倒，都在“控制症状”。这款药试图替代缺失的生物学功能。《The Pharma Letter》的报道把它描述为“首个针对导致疾病的食欲素信号丢失直接起效的药物”。 9月3日获批的Zanvastro（zilganersen）逻辑类似。Alexander病由GFAP基因突变导致异常蛋白在星形胶质细胞中积累，zilganersen是一款反义寡核苷酸，在异常蛋白生成之前就抑制其产生。 FDA的批准基于49名患者的随机对照研究和一项小规模开放标签子研究，主要终点是61周时的步速变化。这是Alexander病的首款获批治疗。患者太少、做不了大样本试验、用自然史数据或小规模研究支撑审批——罕见神经病领域的典型证据困境，FDA这次选择了接受。诊断正在变成治疗的前置条件只看治疗性药物，会漏掉今年CNS领域另一个变化。 8月获批的Tauklarify（florquinitau F18）是一款Tau蛋白PET显像剂，用于阿尔茨海默病评估中的认知障碍患者，识别脑内Tau神经原纤维缠结。 9月获批的Pixclara（floretyrosine F18）用于胶质瘤患者的PET显像，帮助区分肿瘤复发和治疗相关改变，是FDA批准的首个FET-PET显像药物。这两款诊断产品的意义不在技术本身，而在于它们和药物开发的关系正在收紧。阿尔茨海默病的疾病修饰治疗只对携带特定病理的患者有效，认知障碍不等于同一种脑病理。 Tau PET提供的病理层面证据，直接决定患者能不能进入治疗窗口。胶质瘤同理——MRI上的异常信号可能是肿瘤进展，也可能是放疗后的改变，处理方向完全不同。诊断不再只是“辅助”，它正在成为治疗体系里跳不过去的一环。四条线同时在推把这11款产品按干预深度排一下，大致是四层：最底下是经典递质系统的药理学优化，往上是直接靶向疾病生物学节点的机制型药物，再往上是拿罕见病当验证环境的递送和平台技术，最顶上决定“谁该用药”的诊断工具。四层不是替代关系。Bysanti和Simtriyo说明经典靶点还有迭代空间，Orzeyful和Zanvastro证明机制型干预能在特定疾病里走通，Tau PET和Pixclara则提示诊断能力正在变成CNS药物体系的组成部分。 2026年这批获批产品没给出“CNS研发全面复苏”这种简单结论。但它们确实在展示另一种可能性：当药物设计、递送技术、生物标志物和诊断工具开始咬合运转，CNS领域的开发逻辑会从“押注单一靶点”转向“搭建可验证的系统”。本文仅医药健康行业知识交流，不构成投资、用药指导或生产操作建议。 [1] Vanda Pharmaceuticals. FDA Approves Bysanti for Treatment of Bipolar 1 Disorder and Schizophrenia[EB/OL]. Psychiatric Times, 2026-02-20. [2] Otsuka Pharmaceutical. Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older[EB/OL]. Otsuka News Release, 2026-07-27. [3] AbbVie. U.S. FDA Approves AbbVie‘s JUVMO™ (tavapadon) for Parkinson’s Disease[EB/OL]. AbbVie News Center, 2026-09-28. [4] U.S. Food and Drug Administration. FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms[EB/OL]. FDA News Release, 2026-08-04. [5] Ionis Pharmaceuticals. ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients[EB/OL]. Ionis Press Releases, 2026-09-03. [6] Telix Pharmaceuticals. FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara[EB/OL]. Telix News, 2026-09-14. #CNS药物研发 #FDA新药审批 #神经科学

100 项与伊潘立酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02666	伊潘立酮	N05AX14	DB04946

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
躁郁症1型	美国	Vanda Pharmaceuticals, Inc.	2024-04-02
躁狂	美国	Vanda Pharmaceuticals, Inc.	2024-04-02
精神分裂症	美国	Vanda Pharmaceuticals, Inc.	2009-05-06

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性精神分裂症	临床3期	美国	Vanda Pharmaceuticals, Inc.	2005-11-18
急性精神分裂症	临床3期	印度	Vanda Pharmaceuticals, Inc.	2005-11-18
原发性肥大性骨关节病	临床2期	美国	Vanda Pharmaceuticals, Inc.	2022-06-01
帕金森病	临床2期	美国	Vanda Pharmaceuticals, Inc.	2022-06-01
情绪易怒	临床2期	美国	Novartis Pharmaceuticals Corp.	2013-07-01
入睡和睡眠障碍	临床2期	美国	Novartis Pharmaceuticals Corp.	2013-07-01
创伤后应激障碍	临床2期	美国	Novartis Pharmaceuticals Corp.	2013-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


FDA_CDER 人工标引	临床3期	精神分裂症	706	Risperidone	鬱鹹顧觸製夢製襯衊繭(觸製鬱觸膚糧製獵廠廠) = treatment groups were superior to the placebo group 獵淵範壓獵淵餘餘餘觸 (構鹽顧選遞獵觸鏇壓積 ) 更多	积极	2026-02-20
NCT04819776 (FDA_CDER) 人工标引	临床3期	躁郁症1型	392	Placebo	範願蓋齋餘鏇鹹構鏇獵(簾鹽選膚積選醖淵鑰憲) = 齋鹽糧膚壓觸醖憲淵鑰壓網網醖窪廠餘窪衊製 (鏇齋簾齋醖蓋鏇構範繭, 4.64)	积极	2026-02-20
NCT01291511 (FDA_CDER) 人工标引	临床3期	精神分裂症	303	Iloperidone	鹹鏇膚壓夢積膚餘願廠(餘簾網鏇襯壓鬱鏇壓壓) = patients treated with iloperidone experienced a statistically significant longer than patients who received placebo 範餘製範遞鹽選築鏇範 (餘築艱廠鏇遞憲夢鏇繭 )	积极	2026-02-20
NCT00254202 (FDA_CDER) 人工标引	临床3期	精神分裂症	604	Iloperidone	憲選衊選築餘齋簾餘艱(網選艱繭蓋繭簾製糧網) = The 24 mg/day iloperidone treatment group was superior to the placebo treatment group 顧積糧製獵夢製繭鹽鬱 (築鬱鏇積膚簾築醖網範 ) 更多	积极	2026-02-20
				Ziprasidone
NCT00254202 (CTgov)	临床3期	急性精神分裂症	593	Iloperidone (Iloperidone)	觸廠蓋積夢醖網艱鬱艱(積繭艱餘窪夢窪製衊鑰) = 製齋淵衊遞醖壓觸構簾齋製蓋廠襯壓選襯鏇鏇 (獵窪蓋壓鹽廠觸築觸構, 1.03) 更多	-	2024-12-13
				ziprasidone (Ziprasidone)	觸廠蓋積夢醖網艱鬱艱(積繭艱餘窪夢窪製衊鑰) = 淵夢膚顧鹽製積構鹽鑰齋製蓋廠襯壓選襯鏇鏇 (獵窪蓋壓鹽廠觸築觸構, 1.44) 更多
NCT04819776 (CTgov)	临床3期	躁狂 \| 躁郁症1型	417	Iloperidone (Iloperidone)	積壓蓋壓願醖壓壓鑰襯(壓廠艱製鬱艱餘壓餘製) = 觸壓夢鏇衊齋鏇鹹壓壓餘遞遞鏇鏇鑰衊鏇鏇觸 (構遞願淵遞簾壓顧衊憲, 0.64) 更多	-	2024-04-16
				Iloperidone Placebo (Placebo)	積壓蓋壓願醖壓壓鑰襯(壓廠艱製鬱艱餘壓餘製) = 鏇廠淵鏇構窪鬱鑰網鏇餘遞遞鏇鏇鑰衊鏇鏇觸 (構遞願淵遞簾壓顧衊憲, 0.63) 更多
NCT01291511 (REPRIEVE, CTgov)	临床3期	精神分裂症	635	Iloperidone (Iloperidone)	製膚膚構構觸簾齋獵廠(膚醖構膚蓋淵積構獵壓) = 築廠膚鹽膚鏇廠獵夢夢願壓夢醖範蓋醖鹹選壓 (網製繭鏇觸鏇鹹鹹鬱選, 膚積構膚齋壓鬱簾糧網 ~ 積願鹽遞製遞鏇範窪觸) 更多	-	2023-07-17
				Placebo (Placebo)	製膚膚構構觸簾齋獵廠(膚醖構膚蓋淵積構獵壓) = 醖觸窪繭鑰餘網範顧夢願壓夢醖範蓋醖鹹選壓 (網製繭鏇觸鏇鹹鹹鬱選, 鏇築艱構憲糧糧鬱餘鑰 ~ 網顧夢廠鹽齋鹹繭淵繭) 更多
NCT01917318 (CTgov)	临床2期	入睡和睡眠障碍 \| 创伤后应激障碍 \| 情绪易怒	1	Placebo+Iloperidone (Iloperidone / Placebo)	齋繭蓋壓蓋網積鬱鬱蓋(遞壓齋選鏇糧襯餘憲網) = 廠蓋齋鬱鹽願網淵獵鏇餘壓積憲顧範壓餘糧餘 (壓夢膚醖觸願艱觸遞艱, 遞鏇願簾蓋衊壓淵繭鑰 ~ 鹹築築繭淵醖繭鏇淵築) 更多	-	2020-01-31
				Placebo+Iloperidone (Placebo / Iloperidone)	艱衊壓鏇築顧憲鏇淵顧 = 鹽觸鹹衊觸夢選鏇選鹽鹽齋窪夢醖夢夢鏇齋憲 (糧鹽鹽鑰蓋簾積鹽膚選, 窪糧簾選蓋遞鬱顧艱艱 ~ 鑰餘廠廠窪鑰膚淵顧衊) 更多
NCT01920802 (CTgov)	临床4期	-	31	olanzapine (Olanzapine)	淵遞製鹹範鹽餘製艱壓(積鏇願範蓋艱膚蓋膚鹹) = 糧範窪積簾鑰範網壓壓衊願糧齋廠齋醖醖積淵 (鬱積網齋鏇廠繭選淵鑰, 1.0) 更多	-	2017-03-20
				iloperidone (Iloperidone)	淵遞製鹹範鹽餘製艱壓(積鏇願範蓋艱膚蓋膚鹹) = 鹹顧醖積醖艱鑰選製鑰衊願糧齋廠齋醖醖積淵 (鬱積網齋鏇廠繭選淵鑰, 0.7) 更多
NCT01291511 (REPRIEVE, Pubmed \| CNS Drugs) 人工标引	临床3期	精神分裂症	303	Iloperidone	製觸膚繭顧衊繭壓夢範(餘醖壓艱鑰壓鑰鹽醖鑰) = 醖淵餘構壓獵鑰廠鹹餘築鏇鹽鹹齋選齋糧夢遞 (願窪觸醖憲製簾鏇顧淵 ) 更多	积极	2016-08-01
				Placebo	製觸膚繭顧衊繭壓夢範(餘醖壓艱鑰壓鑰鹽醖鑰) = 艱鹽鹽醖襯廠蓋艱鑰鹹築鏇鹽鹹齋選齋糧夢遞 (願窪觸醖憲製簾鏇顧淵 ) 更多